MeSH tree: D03.633.100.786.469
Clinically available KRAS inhibitors mainly target G12C, which is rare in PDAC and often acquires resistance. Oncogenic KRAS inactivates RB1 via CDK4/6, while RB1 mutation is rare. Thus, CDK4/6 inhibition offers an indirect ...
Mar 13, 2026
0
9
Through millions of years of evolutionary refinement, the human body has developed a sophisticated surveillance mechanism—the immune system. This intricate network is constantly scanning the body for invaders such as bacteria, ...
Apr 17, 2024
0
43
Tyrosine kinase inhibitors are a type of targeted cancer medicine that can attack specific types of cancer cells and prevent them from multiplying. Although these inhibitors, called TKIs, can be very useful in fighting certain ...
Mar 17, 2023
0
76
